[
  {
    "sample_notice": "Illustrative payload using DModify schema field conventions; not a commercial data delivery.",
    "schema_version": "1.0.0",
    "dataset": "sec_financial_filings",
    "cik": "0001001233",
    "company_name": "Sangamo Therapeutics, Inc.",
    "form_type": "8-K",
    "filing_date": "2026-09-08",
    "accession_number": "0001104659-26-105905",
    "period_end": "2026-03-31",
    "revenue_usd_millions": 1.44,
    "net_income_usd_millions": -31.0,
    "total_debt_usd_millions": null,
    "cash_usd_millions": 27.59,
    "operating_cash_flow_usd_millions": -19.28,
    "debt_equity_ratio": null,
    "revenue_basis": "Reported revenue",
    "operating_cash_flow_basis": "fiscal YTD",
    "financial_data_source": "Latest 10-Q filed 2026-05-14; accn 0001628280-26-035067",
    "financial_source_form_type": "10-Q",
    "financial_source_filing_date": "2026-05-14",
    "financial_source_accession_number": "0001628280-26-035067",
    "financial_source_filing_url": "https://www.sec.gov/Archives/edgar/data/1001233/000162828026035067/",
    "source_system": "SEC EDGAR",
    "source_filing_url": "https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/",
    "data_quality_status": "PASS",
    "data_quality_messages": []
  }
]